BUB1B and lip and oral cavity carcinoma: Given the increasing recognition of MB, TP53, CENPA, BUB1B, MAD2L and ZWINT as promising biomarkers for predicting patient outcomes, modulating immune responses, and guiding treatment strategies in oral cancer, we conducted a thorough investigation of their expression patterns in 25 oral cancer tissues and 25 adjacent normal tissues using RT-qPCR.